U.S. markets closed

  • S&P 500

    4,320.06
    -9.94 (-0.23%)
     

  • Dow 30

    33,963.84
    -106.58 (-0.31%)
     

  • Nasdaq

    13,211.81
    -12.18 (-0.09%)
     

  • Russell 2000

    1,776.50
    -5.32 (-0.30%)
     

  • Crude Oil

    90.33
    +0.70 (+0.78%)
     

  • Gold

    1,944.90
    +5.30 (+0.27%)
     

  • Silver

    23.82
    +0.13 (+0.56%)
     

  • EUR/USD

    1.0647
    -0.0015 (-0.14%)
     

  • 10-Yr Bond

    4.4380
    -0.0420 (-0.94%)
     

  • GBP/USD

    1.2240
    -0.0054 (-0.44%)
     

  • USD/JPY

    148.3600
    +0.7970 (+0.54%)
     

  • Bitcoin USD

    26,589.80
    +12.57 (+0.05%)
     

  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     

  • FTSE 100

    7,683.91
    +5.29 (+0.07%)
     

  • Nikkei 225

    32,402.41
    -168.62 (-0.52%)
     

Vertex/CRISPR Partnered Cell Therapy Shows Encouraging Response In Sickle Cell Disease, Thalassemia Patients

Vandana Singh
·2 min read

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and CRISPR Therapeutics AG (NASDAQ: CRSP) announced that pivotal trials for exagamglogene autotemcel (exa-cel) for transfusion-dependent beta-thalassemia (TDT) or severe sickle cell disease (SCD) met primary and key secondary endpoints at pre-specified interim analyses.

Of the 48 patients with TDT who had received exa-cel at the time of the analysis, 24/27 (88.9%) achieved the primary endpoint of transfusion independence for at least 12 consecutive months (TI12) and the secondary endpoint of transfusion independence for at least 6 consecutive months (TI6) with mean weighted hemoglobin of at least 9 g/dL.

The mean duration of transfusion independence was 20.5 months, with a maximum of 40.7 months.

The mean proportion of edited BCL11A alleles was stable in the bone marrow and peripheral blood over time, indicating successful permanent editing in long-term hematopoietic stem cells.

Of the 35 patients with SCD who had received exa-cel at the time of the analysis, 16/17 (94.1%) achieved the primary endpoint of freedom from vaso-occlusive crises (VOCs) for at least 12 consecutive months (VF12).

The mean duration of VOC-free was 18.7 months, with a maximum of 36.5 months. 17/17 (100%) achieved the key secondary endpoint of being free from VOC-related hospitalizations for at least 12 consecutive months.

In the analysis of all patients who received exa-cel, mean fetal hemoglobin was more than 30% of total hemoglobin by Month 3 and was then maintained at approximately 40.0%.

The FDA has accepted the application for exa-cel for sickle cell disease and transfusion-dependent beta-thalassemia (TDT).

The FDA has granted priority review for exa-cel in SCD with a PDUFA date of December 8, 2023, and standard review for TDT with a PDUFA date of March 30, 2024.

Price Action: VRTX shares are up 0.61% at $334.39, and CRSP shares are down 1.79% at $61.47 on the last check Friday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Vertex/CRISPR Partnered Cell Therapy Shows Encouraging Response In Sickle Cell Disease, Thalassemia Patients originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.